2 Beaten-Down Stocks With Incredible Upside Potential

Group 1: Iovance Biotherapeutics - Iovance Biotherapeutics specializes in cancer treatment and received approval for Amtagvi, a therapy for advanced melanoma, which is the first of its kind for solid tumors [3][4] - The company generated $164.1 million in revenue last year, a significant increase from the previous year when it had minimal revenue [4] - Despite the approval and revenue growth, the stock has underperformed due to market dynamics and the complexity of administering TIL therapies, which take 34 days to manufacture [5] - The stock is currently priced under$4 per share, and the company is pursuing regulatory approvals and label expansions for Amtagvi, which could lead to significant upside potential [6] Group 2: CRISPR Therapeutics - CRISPR Therapeutics develops gene-editing therapies using the CRISPR/Cas9 technique and received approval for Casgevy, the first CRISPR medicine, which treats rare blood disorders [8] - The company has not generated substantial revenue since the approval, as manufacturing ex vivo gene-editing therapies is complex and time-consuming [9] - Casgevy is priced at $2.2 million in the U.S., targeting a market of approximately 58,000 patients with minimal competition, indicating potential for significant revenue once it gains traction [10] - The company has delivered returns comparable to the broader market since its IPO in 2016, and long-term investors may benefit from future breakthroughs in gene-editing products [11][13]